ArticlePediatric surgery international2025
Safety of 200iU of intravesical Botox in children of all ages with functional urinary incontinence.
Article in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intravesical Botox: An Effective Therapy for Refractory Monosymptomatic Nocturnal Enuresis.Journal of paediatrics and child health · 2026Article
- Intravesical botox as an effective therapy for giggle incontinence in children.Pediatric surgery international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntravesical Botox injection can be effective in children with functional urinary incontinence refractory to conservative measures. A wide range of potential doses have been reported with concerns regarding the safety of higher doses. This study aims to determine the safety and side effect profile of 200iU of Botox in children of all ages with functional urinary incontinence.
methodsA retrospective review of 143 children who received 200iU of botulinum toxin A utilising intradetrusor injections was performed. All children had urinary incontinence with no defined neurological abnormality. Post-operative complications were analysed, including UTI, adverse drug reactions, pain, haematuria, urinary retention, transitory increased incontinence and systemic adverse effects.
resultsA total of 228 injection procedures (range: 1-6 procedures) in 143 children (70 girls, 73 boys) were included. Median age at first treatment was 9 years (range: 4-17 years). The mean number of treatment cycles required per patient was 1.59 (range: 1-6). There were no intra-operative complications. Post-operative complications included UTI, post-operative pain and haematuria. No complication required re-admission and no cases of urinary retention requiring catheterisation occurred.
conclusionThis study represents the largest population to date of children with functional urinary incontinence treated with intravesical Botox, confirming this as a well-tolerated, safe intervention in all ages with complications as would be expected for cystoscopy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.